EMAIL THIS PAGE TO A FRIEND

Journal of clinical biochemistry and nutrition

Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors.


PMID 28584401

Abstract

It is important to establish effective methods for preventing colorectal cancer because the number of colorectal cancer deaths is increasing. Erythromycin one of the macrolide antibiotics, has been shown to exert pleiotropic effects, such as anti-inflammatory and anti-oxidative effects, on mammalian cells. In the present study, we aimed to evaluate the preventive effects of erythromycin on intestinal carcinogenesis. We first confirmed that erythromycin suppresses the transcriptional activity of nuclear factor-κB and activator protein-1 and the expression of its downstream targets, interleukin-6 and cyclooxygenase-2 in human colon cancer cells. Next, we fed 5-week-old male

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H9415
5HPP-33, ≥98% (HPLC), solid
C20H21NO3